-
Board Certification
American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
4.9 /5( out of 56 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.August 19, 2024SUGAR HOUSE HEALTH CENTERPositive, asked questions clearly, conversational, She is thorough, intelligent, Considers treatment options, asks my opinion, gave clear explanations,
August 11, 2024SUGAR HOUSE HEALTH CENTERKristina Woolsey really listened and made me feel heard. She treated me with respect and I now feel like I have someone in my corner helping me identify and treat my health issues. I trust her immensely.
July 31, 2024HUNTSMAN CANCER CENTERDr. Chalmers has been with me for over 8 years of fighting these rare tumors. She is always caring and knowledgable.
July 30, 2024HUNTSMAN CANCER CENTERAlways kind and caring - excellent care provider.
July 18, 2024HUNTSMAN CANCER CENTERSHE A SUPER PERSON AND SUPER DOCTOR
July 17, 2024HUNTSMAN CANCER CENTERI have been coming to Huntsman for 10 years for treatments, have seen many very good Dr.'s. But without a doubt, Dr. Chalmers is one of the BEST! She treats me not only as her patient first, but also cares about me a person!
June 04, 2024HUNTSMAN CANCER CENTERIf you need a cancer doctor, Doctor Chalmers is peerless!
April 10, 2024HUNTSMAN CANCER CENTEREs una experiencia muy buena ya que ella es una Doctora muy profesional en su trabajo siempre preocupada y viendo lo mejor para mi como pasiente.muchas gracias.
February 23, 2024HUNTSMAN CANCER CENTERHannah is intelligently disabled and I liked how Dr. Chalmers included both [NAME REMOVED] and I l, her mother, when speaking about her condition and treatment.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Board Certification American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology and Medical Oncology - Rush University Medical Center Fellow Internal Medicine - Rush University Medical Center Resident Professional Medical Medicine - Drexel University College of Medicine M.D. Dartmouth College B.A. Selected Publications
Journal Article
- Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley W (2023). Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide(TM). Neurooncol Adv, 6(1), vdad150. (Read full article)
- Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, 16(4), e313-e323. (Read full article)
- Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. (Read full article)
- Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972. (Read full article)
Editorial
- Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200. (Read full article)
Letter
- Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340. (Read full article)
-
News & Podcasts
Huntsman Cancer Institute News